Literature DB >> 6613481

The influence of heparin and curable resection on the survival of colorectal cancer.

S Törngren, A Rieger.   

Abstract

During a five-year period 271 patients were operated on for cure of colorectal cancer. Heparin in low doses was given to 114 patients according to a thromboprophylactic routine. No thromboprophylactic agents were given to 157 patients. In all other respects treatment of the colorectal cancer was the same. Mean age and sex were the same for the two groups. The distribution according to Dukes' classification did not differ statistically. The 3-year survival and deaths due to cancer were registered for both groups. Crude survival rate and survival probability were calculated. No significant differences were found between patients receiving and not receiving heparin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613481

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  5 in total

1.  Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer?

Authors:  R D Kingston; J W Fielding; M K Palmer
Journal:  Int J Colorectal Dis       Date:  1993-07       Impact factor: 2.571

2.  The first international urokinase/warfarin trial in colorectal cancer.

Authors:  L Daly
Journal:  Clin Exp Metastasis       Date:  1991 Jan-Feb       Impact factor: 5.150

Review 3.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

4.  Rectal bleeding and previous anticoagulant treatment in patients with colorectal cancer do not predict outcome.

Authors:  B Kirshtein; S Ariad; S Mizrahi; S Man; S Walfisch
Journal:  Tech Coloproctol       Date:  2007-05-25       Impact factor: 3.781

Review 5.  Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Authors:  I García-Escobar; C Beato-Zambrano; J Muñoz Langa; E Brozos Vázquez; B Obispo Portero; D Gutiérrez-Abad; A J Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2018-02-22       Impact factor: 3.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.